# Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

> **NCT06802328** · — · AVAILABLE · sponsor: **Tiziana Life Sciences LTD**

## Conditions studied

- Non-Active Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Foralumab TZLS-401 50 µg

## Key facts

- **NCT ID:** NCT06802328
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06802328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06802328, "Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06802328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*